Investment
Investment Highlights
- LC101 development was completed and led by the inventor of the branded Doxil®
- Signed strategic agreement with tier 1 pharma company to commercialize LC101 in the U.S. market
- Obtained FDA US marketing authorisation for LC101
- FDA accredited, cGMP manufacturing facility secured to support commercial launch
- Overall $500m ww market opportunity with very few competitors due to high entry barriers
(i.e. complex nano-drug)
Upcoming Catalysts
- LC101 obtained FDA US marketing authorisation
- Further international expansion (e.g. China) of LC101 via on-going BD efforts
- Pipeline of Liposomal products based on Ayana’s platform technology are in development